The side effect profile of Clozapine in real world data of three large mental hospitals

Objective: Mining the data contained within Electronic Health Records (EHRs) can potentially generate a greater understanding of medication effects in the real world, complementing what we know from Randomised control trials (RCTs). We Propose a text mining approach to detect adverse events and medication episodes from the clinical text to enhance our understanding of adverse effects related to Clozapine, the most effective antipsychotic drug for the management of treatment-resistant schizophrenia, but underutilised due to concerns over its side effects. Material and Methods: We used data from de-identified EHRs of three mental health trusts in the UK (>50 million documents, over 500,000 patients, 2835 of which were prescribed Clozapine). We explored the prevalence of 33 adverse effects by age, gender, ethnicity, smoking status and admission type three months before and after the patients started Clozapine treatment. We compared the prevalence of adverse effects with those reported in the Side Effects Resource (SIDER) where possible. Results: Sedation, fatigue, agitation, dizziness, hypersalivation, weight gain, tachycardia, headache, constipation and confusion were amongst the highest recorded Clozapine adverse effect in the three months following the start of treatment. Higher percentages of all adverse effects were found in the first month of Clozapine therapy. Using a significance level of (p< 0.05) out chi-square tests show a significant association between most of the ADRs in smoking status and hospital admissions and some in gender and age groups. Further, the data was combined from three trusts, and chi-square tests were applied to estimate the average effect of ADRs in each monthly interval. Conclusion: A better understanding of how the drug works in the real world can complement clinical trials and precision medicine.

[1]  P. Vuopio,et al.  Agranulocytosis in patients treated with clozapine , 1977, Acta psychiatrica Scandinavica.

[2]  R. Poland,et al.  Ethnicity and psychopharmacology , 1986, Culture, medicine and psychiatry.

[3]  J. Lieberman,et al.  Update on the clinical efficacy and side effects of clozapine. , 1991, Schizophrenia bulletin.

[4]  P. Krupp,et al.  Clozapine-Associated Agranulocytosis: Risk and Aetiology , 1992, British Journal of Psychiatry.

[5]  R. Leadbetter,et al.  Clozapine-induced weight gain: prevalence and clinical relevance. , 1992, The American journal of psychiatry.

[6]  J. Lohr,et al.  Smoking and schizophrenia , 1992, Schizophrenia Research.

[7]  J. Lieberman,et al.  Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. , 1993, The New England journal of medicine.

[8]  J. Rapoport,et al.  An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. , 1994, Journal of the American Academy of Child and Adolescent Psychiatry.

[9]  J. Rapoport,et al.  Childhood-onset schizophrenia: A double-blind clozapine-haloperidol comparison , 1996 .

[10]  S. Stahl,et al.  Book Review: Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 2nd Edition , 1996 .

[11]  Abraham Weizman,et al.  An open trial of clozapine in neuroleptic-resistant childhood-onset schizophrenia , 1997, British Journal of Psychiatry.

[12]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[13]  C. Mazure,et al.  Management of the adverse effects of clozapine. , 1998, Schizophrenia bulletin.

[14]  J. Rapoport,et al.  Elevated prolactin in pediatric patients on typical and atypical antipsychotics. , 1999, Journal of child and adolescent psychopharmacology.

[15]  Del D. Miller,et al.  Review and management of clozapine side effects. , 2000, The Journal of clinical psychiatry.

[16]  R. McCreadie,et al.  Cigarette smoking and schizophrenia , 2000 .

[17]  M. Angermeyer,et al.  Patients' and relatives' assessment of clozapine treatment , 2001, Psychological Medicine.

[18]  M. Rademaker Do Women Have More Adverse Drug Reactions? , 2001, American journal of clinical dermatology.

[19]  M. Anthony,et al.  Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part I. , 2002, Journal of women's health & gender-based medicine.

[20]  H. Nasrallah,et al.  Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. , 2002, The Journal of clinical psychiatry.

[21]  P. Schulte What is an Adequate Trial with Clozapine? , 2003, Clinical pharmacokinetics.

[22]  M. Olkinuora,et al.  Agranulocytosis during treatment with clozapine , 1977, European Journal of Clinical Pharmacology.

[23]  M. Pirmohamed,et al.  Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients , 2004, BMJ : British Medical Journal.

[24]  L. Citrome The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents. , 2004, Drugs of today.

[25]  H. Remschmidt,et al.  Chart review for potential features of myocarditis, pericarditis, and cardiomyopathy in children and adolescents treated with clozapine. , 2004, Journal of child and adolescent psychopharmacology.

[26]  D. Cohen Atypical Antipsychotics and New Onset Diabetes mellitus , 2004, Pharmacopsychiatry.

[27]  S. Kumra,et al.  Hematological adverse events in clozapine-treated children and adolescents. , 2005, Journal of the American Academy of Child and Adolescent Psychiatry.

[28]  J. Lieberman,et al.  Clinical profile of clozapine: Adverse reactions and agranulocytosis , 2005, Psychiatric Quarterly.

[29]  B. Herpertz-Dahlmann,et al.  Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics. , 2006, Journal of child and adolescent psychopharmacology.

[30]  B. Disilvio,et al.  Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats. , 2007, Life sciences.

[31]  T. Furukawa,et al.  Regulation of cardiac ion channels via non-genomic action of sex steroid hormones: implication for the gender difference in cardiac arrhythmias. , 2007, Pharmacology & therapeutics.

[32]  Julie Kreyenbuhl,et al.  Clozapine underutilization and discontinuation in African Americans due to leucopenia. , 2007, Schizophrenia bulletin.

[33]  J. McNeil,et al.  Clozapine-Associated Myocarditis , 2007, Drug safety.

[34]  J. Rapoport,et al.  Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.

[35]  B. Herpertz-Dahlmann,et al.  Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone , 2008, Journal of Neural Transmission.

[36]  I. Chaudhry,et al.  Ethnicity and psychopharmacology , 2008, Journal of psychopharmacology.

[37]  R. Flanagan Side effects of clozapine and some other psychoactive drugs. , 2008, Current Drug Safety.

[38]  Kay A. Hodge,et al.  Side-effects and treatment with clozapine: a comparison between the views of consumers and their clinicians. , 2008, International journal of mental health nursing.

[39]  E. Russo,et al.  The safety of clozapine in the elderly , 2008, Expert opinion on drug safety.

[40]  Shu-Feng Zhou,et al.  Insights into the Substrate Specificity, Inhibitors, Regulation, and Polymorphisms and the Clinical Impact of Human Cytochrome P450 1A2 , 2009, The AAPS Journal.

[41]  David Taylor,et al.  Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection. , 2009, The British journal of psychiatry : the journal of mental science.

[42]  Graham Thornicroft,et al.  The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: development and descriptive data , 2009, BMC psychiatry.

[43]  C. Correll,et al.  Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia Patients , 2010, Neuropsychopharmacology.

[44]  A. Mortimer,et al.  Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world. , 2010, Clinical schizophrenia & related psychoses.

[45]  B. Stricker,et al.  Sex-related differences in hospital admissions attributed to adverse drug reactions in the Netherlands. , 2011, British journal of clinical pharmacology.

[46]  D. Classen,et al.  'Global trigger tool' shows that adverse events in hospitals may be ten times greater than previously measured. , 2011, Health affairs.

[47]  C Hofer-Dueckelmann,et al.  Adverse drug reactions (ADRs) associated with hospital admissions - elderly female patients are at highest risk. , 2011, International journal of clinical pharmacology and therapeutics.

[48]  M. Raja Clozapine safety, 35 years later. , 2011, Current drug safety.

[49]  R. Altman,et al.  Data-Driven Prediction of Drug Effects and Interactions , 2012, Science Translational Medicine.

[50]  M. Picchioni,et al.  A systematic review of the evidence of clozapine's anti-aggressive effects. , 2012, The international journal of neuropsychopharmacology.

[51]  F. Dickerson,et al.  Cigarette smoking among persons with schizophrenia or bipolar disorder in routine clinical settings, 1999-2011. , 2012, Psychiatric services.

[52]  Jennifer H. Martin,et al.  Smoking and drug interactions , 2013 .

[53]  S. Frangou,et al.  Systematic review of the efficacy and tolerability of Clozapine in the treatment of youth with early onset schizophrenia , 2014, European psychiatry.

[54]  E. Russo,et al.  Rare and very rare adverse effects of clozapine , 2015, Neuropsychiatric disease and treatment.

[55]  F. Gaughran,et al.  Glasgow Antipsychotic Side-effects Scale for Clozapine — Development and validation of a clozapine-specific side-effects scale , 2015, Schizophrenia Research.

[56]  Matthew Broadbent,et al.  The Effect of Clozapine on Premature Mortality: An Assessment of Clinical Monitoring and Other Potential Confounders , 2014, Schizophrenia bulletin.

[57]  J. MacCabe,et al.  Predictors of long-term (≥ 6 months) antipsychotic polypharmacy prescribing in secondary mental healthcare , 2016, Schizophrenia Research.

[58]  N. Kar,et al.  Clozapine Monitoring in Clinical Practice: Beyond the Mandatory Requirement , 2016, Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology.

[59]  Peer Bork,et al.  The SIDER database of drugs and side effects , 2015, Nucleic Acids Res..

[60]  Consistency between clinician and patient ratings of clozapine-induced side effects , 2016, Schizophrenia Research.

[61]  Andrea C. Fernandes,et al.  Cohort profile of the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLaM BRC) Case Register: current status and recent enhancement of an Electronic Mental Health Record-derived data resource , 2016, BMJ Open.

[62]  Zina M. Ibrahim,et al.  ADEPt, a semantically-enriched pipeline for extracting adverse drug events from free-text electronic health records , 2017, PloS one.

[63]  G. Gürcan,et al.  Side Effects of Clozapine and Their Relationship with Clinical Variables in Patients with Schizophrenia , 2017, European Psychiatry.

[64]  R. Dobson,et al.  Trajectories of dementia-related cognitive decline in a large mental health records derived patient cohort , 2017, PloS one.

[65]  R. Stewart,et al.  The Camden & Islington Research Database: Using electronic mental health records for research , 2018, PloS one.